Newsroom

Lotus 本日の公告にCalcium Acetate Capsule学名は、正式に米国FDA公式承認を取得し、薬の証明書を取得

Posted on 27.7.2016

Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan OTC stock code: 1795) today announced that its ANDA (“Abbreviated New Drug Application”) of Calcium Acetate Capsule 667mg for renal disease has been officially approved by US FDA. The Company will start the preparation for product commercialization in the US market accordingly.

Calcium Acetate Capsule is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal diseases. Upon litigation settlement, Lotus received the approval earlier than expected. Lotus now is capable of offering a comprehensive portfolio in the US market. Additionally, this is the fourth US ANDA approval Lotus has received since the beginning of 2016, after the approvals of Paricalcitol, Temozolomide and Levetiracetam. It further solidifies the growth momentum for Lotus’ export business in 2016 and beyond.